Israel Englander’s Dyne Therapeutics DYN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.59M Buy
431,850
+273,302
+172% +$5.08M ﹤0.01% 2317
2026
Q1
$2.87M Sell
158,548
-745,841
-82% -$12.9M ﹤0.01% 3513
2025
Q4
$17.7M Buy
904,389
+490,449
+118% +$9.29M 0.01% 1697
2025
Q3
$5.24M Buy
413,940
+271,221
+190% +$3.09M ﹤0.01% 3103
2025
Q2
$1.36M Buy
142,719
+64,540
+83% +$711K ﹤0.01% 4195
2025
Q1
$818K Buy
78,179
+40,643
+108% +$581K ﹤0.01% 4499
2024
Q4
$884K Buy
37,536
+31,545
+527% +$933K ﹤0.01% 4299
2024
Q3
$215K Buy
+5,991
New +$238K ﹤0.01% 5409
2024
Q2
Sell
-18,011
Closed -$511K 6016
2024
Q1
$511K Sell
18,011
-370,079
-95% -$8.37M ﹤0.01% 4801
2023
Q4
$5.16M Buy
+388,090
New +$3.79M ﹤0.01% 2764
2023
Q2
Sell
-190,363
Closed -$2.19M 6211
2023
Q1
$2.19M Sell
190,363
-63,747
-25% -$828K ﹤0.01% 3356
2022
Q4
$2.94M Buy
254,110
+172,159
+210% +$1.99M ﹤0.01% 3230
2022
Q3
$1.04M Buy
+81,951
New +$940K ﹤0.01% 4308
2021
Q1
Sell
-38,590
Closed -$810K 6042
2020
Q4
$810K Sell
38,590
-155,475
-80% -$3.08M ﹤0.01% 3868
2020
Q3
$3.92K Buy
+194,065
New +$4.26M ﹤0.01% 2058

Other funds holding DYN

Israel Englander's DYN Position: Q2 2026 in Review

Israel Englander increased its Dyne Therapeutics (DYN) stake by 172% in Q2 2026, buying an estimated $5.08M and bringing the position to 431,850 shares worth $9.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2317.

Israel Englander first reported a position in DYN in Q3 2020 and has held it in 15 quarters since. The position peaked at $17.7M in Q4 2025. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Israel Englander held 431,850 shares of Dyne Therapeutics worth $9.59M as of Q2 2026.
  • Israel Englander bought 273,302 Dyne Therapeutics shares in Q2 2026, an estimated $5.08M.
  • Dyne Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2317 holding.
  • Israel Englander first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 15 quarters since.
  • Israel Englander's Dyne Therapeutics position peaked at $17.7M in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.